Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Details
Category: Globe NewsWire News Distribution Service

TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will…


Posted: 2024-12-05 23:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

teva | press | release | announces | agreement


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan - Newscast

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

Mon, 13 Jan 2025 08:05:00 GMT Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Teva inks partnership with Klinge to launch Eylea biosimilar in Europe

Sun, 12 Jan 2025 23:30:00 GMT Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with Klinge Biopharma and Formycon AG, for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to ...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Sun, 12 Jan 2025 23:00:00 GMT Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to ...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Sun, 12 Jan 2025 22:00:00 GMT Under the terms of the agreement ... more about how Teva is all in for better health, visit www.tevapharm.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains ...

Teva Pharmaceutical Industries Limited (TEVA)

Sun, 12 Jan 2025 16:00:00 GMT An archive TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth ... free Teva ...


Blow Us A Whistle